<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04315922</url>
  </required_header>
  <id_info>
    <org_study_id>Synergy ID 390857198 SMB</org_study_id>
    <nct_id>NCT04315922</nct_id>
  </id_info>
  <brief_title>Multiomics Targeting Microbiome Associated Changes in Stroke Patients (StrokeMicroBiomics)</brief_title>
  <acronym>SMB</acronym>
  <official_title>Multiomics Targeting Microbiome Associated Changes in Stroke Patients (StrokeMicroBiomics)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Luxembourg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preclinical research has established a convincing connection between changes in the gut&#xD;
      microbiota composition and stroke outcome. However clinical data on the gut-brain axis, and&#xD;
      its chronic characteristics, is sparse. Additional investigations in the context of ischemic&#xD;
      stroke regarding the relationship between dysbiosis and functional changes of the microbiome,&#xD;
      as characterized by the metabolome, are still required. The StrokeMicroBiomics study will&#xD;
      offer insight into these mechanisms and offer new potential targets for therapeutic&#xD;
      interventions.&#xD;
&#xD;
      The primary objective is the characterisation of gut dysbiosis in ischemic stroke patients in&#xD;
      the acute phase after stroke and during a 3 month follow-up period.&#xD;
&#xD;
      The secondary objectives include the identification of dysregulated gut microbiome&#xD;
      metabolites and key immune cell populations in addition to the clinical progression of the&#xD;
      study participants during the 3 month follow-up period after disease onset.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Results of experimental, preclinical studies suggest that microbiome-targeted may improve&#xD;
      stroke outcome as well as stroke-related comorbidities. Yet, clinical trials describing the&#xD;
      extent and time course of microbiome changes after stroke are currently not available.&#xD;
      Moreover, the impact of post-stroke dysbiosis on metabolic changes and the systemic immunity&#xD;
      are unexplored.&#xD;
&#xD;
      Therefore, the primary objective of this trial is the characterization of gut dysbiosis&#xD;
      progression in ischemic stroke patients during a 3 month follow-up period .&#xD;
&#xD;
      The secondary objectives include the identification of dysregulated gut microbiome&#xD;
      metabolites and key immune cell populations in addition to the clinical progression of the&#xD;
      study participants during the 3 month follow-up period after disease onset.&#xD;
&#xD;
      In order to elucidate the differential impact of lesion size on immune and microbiome&#xD;
      homeostasis, separate patient cohorts with mild and severe stroke will be studied.&#xD;
&#xD;
      Furthermore, to control for the effects of temporary focal neurological deficits and stress&#xD;
      induced microbiome and immune changes, patients with stroke mimics and transient ischemic&#xD;
      attacks (TIA) are being recruited to the control group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from Baseline in the Gut Microbiome Composition at 3 Months post Stroke/TIA</measure>
    <time_frame>1-7 Days and 90 Days after Stroke</time_frame>
    <description>Gut Microbiome Composition is assessed using Shotgun Sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from Baseline of the Gut Metabolome as measured in Blood and Stool at 3 Months post Stroke/TIA</measure>
    <time_frame>1-7 Days and 90 Days after Stroke</time_frame>
    <description>The Metabolome is measured using Mass-Spectometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from Baseline in key Immune Populations at 3 Months post Stroke/TIA</measure>
    <time_frame>1-7 Days and 90 Days after Stroke</time_frame>
    <description>Immune Populations are measured using Flow Cytometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health Stroke Scale (NIHSS)</measure>
    <time_frame>1-7 days and 90 days after stroke</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Score (mRS)</measure>
    <time_frame>1-7 days and 90 days after stroke</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CT and (if available) MRI documentation</measure>
    <time_frame>1-7 days and 90 days after stroke</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Transient Ischemic Attack</condition>
  <arm_group>
    <arm_group_label>Severe Ischemic Stroke</arm_group_label>
    <description>Severe Stroke as defined by inclusion criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Ischemic Stroke</arm_group_label>
    <description>Mild Stroke as defined by inclusion criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transient Ischemic Attack</arm_group_label>
    <description>Transient Ischemic Attack as defined by inclusion criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Microbiome and Plasma Characterisation</intervention_name>
    <description>Flow Cytometry, Mass-Spectometry, Shotgun-Sequencing</description>
    <arm_group_label>Mild Ischemic Stroke</arm_group_label>
    <arm_group_label>Severe Ischemic Stroke</arm_group_label>
    <arm_group_label>Transient Ischemic Attack</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool and blood samples collected at both acute and chronic timepoints from study&#xD;
      participants are stored at -80°C in on-site Biobank.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants are recruited and samples taken within 7 days of either stroke or TIA disease&#xD;
        onset.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written consent as submitted and approved to the human subjects review board must be&#xD;
             gathered from the participants&#xD;
&#xD;
          -  Participants must be at least 50 years of age&#xD;
&#xD;
        For the severe stroke cohort, eligibility is defined by:&#xD;
&#xD;
          -  CT or MRI confirmed ischemic stroke affecting at least 1/3 of the anterior, medial or&#xD;
             posterior cerebral arteries cortical coverage&#xD;
&#xD;
          -  NIHSS of at least 10 at time of induction into emergency room&#xD;
&#xD;
          -  Ischemic Stroke occured within the last 7 days&#xD;
&#xD;
        For the mild stroke cohort, eligibility is defined by:&#xD;
&#xD;
          -  CT or MRI confirmed ischemic stroke affecting no more than 1/3 of the anterior, medial&#xD;
             or posterior cerebral arteries cortical coverage&#xD;
&#xD;
          -  NIHSS between 1 and 10 at time of induction into emergency room&#xD;
&#xD;
          -  Ischemic Stroke occured within the last 7 days&#xD;
&#xD;
        For the TIA cohort, eligibility is defined by:&#xD;
&#xD;
          -  CT or MRI confirmed absence of a lesion&#xD;
&#xD;
          -  NIHSS of 0 no more than 24 hours after induction into emergency room&#xD;
&#xD;
          -  TIA occured within the last 7 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Diagnosed and malignant Tumor ailment&#xD;
&#xD;
          -  Active, non-stroke related immunosuppression (i.e. HIV)&#xD;
&#xD;
          -  Infection, operative procedure or antibiotics treatment within 4 weeks prior to&#xD;
             stroke/TIA&#xD;
&#xD;
          -  Relevant autoimmune disease (i.e Morbus Crohn)&#xD;
&#xD;
          -  Chronic infectious diseases (i.e Hepatitis C)&#xD;
&#xD;
          -  Hemorrhagic Stroke or intracranial bleeding&#xD;
&#xD;
          -  Cerebellar lesions&#xD;
&#xD;
          -  Other neurodegenerative diseases (i.e. Parkinson´s Disease or Alzheimers Dementia)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philip W Melton</last_name>
    <phone>0176 31271941</phone>
    <phone_ext>+49</phone_ext>
    <email>philip.melton@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arthur Liesz, MD</last_name>
    <email>Arthur.Liesz@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum der Universität München - Standort Großhadern</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip W Melton</last_name>
      <phone>0176 31271941</phone>
      <phone_ext>+49</phone_ext>
      <email>philip.melton@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Arthur Liesz, MD</last_name>
      <email>arthur.liesz@med.uni-muenchen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 12, 2020</study_first_submitted>
  <study_first_submitted_qc>March 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2020</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Philip William Melton</investigator_full_name>
    <investigator_title>Cand. med.</investigator_title>
  </responsible_party>
  <keyword>Microbiome</keyword>
  <keyword>Immune System</keyword>
  <keyword>Metabolome</keyword>
  <keyword>Brain Lesion</keyword>
  <keyword>Gut-Brain Axis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

